Status:
COMPLETED
Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection
Lead Sponsor:
Centre Leon Berard
Conditions:
Sars-CoV2
Cancer
Eligibility:
All Genders
Brief Summary
National multicentre epidemiological study to describe retrospectively and prospectively the clinical outcomes of patients with a suspected coronavirus infection (either confirmed or not) while receiv...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- I1. Confirmed diagnosis of any type of solid or hematologic tumor;
- I2. Ongoing anticancer treatment (cytotoxic, targeted therapy, immunotherapy or loco regional procedure, including radiotherapy, surgery or interventional radiology procedure) at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure) ;
- I3. Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever (\>38°C) and/or respiratory tract symptoms), either confirmed or not.
- Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or negative) and/or chest imaging. Note 2: Patients will be eligible regardless of the presence of a neutropenia (either febrile or not) ;
- I4. Patient and/or family did not decline data collection after complete information.
Exclusion
Key Trial Info
Start Date :
April 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
1231 Patients enrolled
Trial Details
Trial ID
NCT04363632
Start Date
April 2 2020
End Date
June 30 2020
Last Update
July 1 2020
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Bergonié
Bordeaux, France
2
Centre François Baclesse
Caen, France, 14076
3
Centre Hospitalier Métropole Savoie
Chambéry, France, 73011
4
Centre Jean Perrin
Clermont-Ferrand, France, 63011